The risk of all-cause death is 8.8 times higher than that of the general population! Complications of HSCT should not be underestimated

Hematopoietic stem cell transplantation (HSCT) is a treatment method that removes tumor cells or abnormal clonal cells in the recipient's body through high-dose radiotherapy and chemotherapy or other immunosuppressive pretreatment, blocks the pathogenesis, and then transplants autologous or allogeneic hematopoietic stem cells to the recipient, so that the recipient can rebuild normal hematopoietic and immune to achieve the purpose of treatment
.
Adequate transfusion of hematopoietic stem cells is a key factor
in rebuilding blood immunity after HSCT.
Hematopoietic stem cells have self-replication and proliferation and differentiation functions, HSCs enter the recipient, can settle in their bodies, proliferate and differentiate into directed progenitor cells, and gradually become mature red blood cells, white blood cells, platelets and other blood cells, and through self-replication, implanted hematopoietic stem cells maintain long-lasting hematopoietic immunity
.
Transplant types are classified
according to the source of hematopoietic stem cells, immunogenetics, and blood relationship of the donor.
Classification of hematopoietic stem cell transplantation The BMTS cohort studied long-term outcomes
in patients who survived ≥ 2 years after Allo-HSCT was performed between January 1, 1974 and December 31, 2014 at the University of Minnesota or the University of Alabama at Birmingham.
Patients in this cohort had an 8.
8-fold higher risk of all-cause mortality than the general population (95% CI, 8.
4 to 9.
3).

It can be seen that the occurrence of transplant-related complications is still a difficult problem, and its prevention and treatment can directly affect the effect of transplantation and the long-term survival and quality
of life of patients.